- Axsome Therapeutics to Present at Upcoming Investor Conferences
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
- Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
More ▼
Key statistics
As of last trade, Axsome Therapeutics Inc (19X:STU) traded at 69.68, 33.03% above the 52 week low of 52.38 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 69.68 |
---|---|
High | 69.68 |
Low | 69.68 |
Bid | 71.00 |
Offer | 72.28 |
Previous close | 70.50 |
Average volume | 104.22 |
---|---|
Shares outstanding | 47.49m |
Free float | 38.36m |
P/E (TTM) | -- |
Market cap | 3.65bn USD |
EPS (TTM) | -6.38 USD |
Data delayed at least 15 minutes, as of May 07 2024.
More ▼